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G protein-coupled receptors (GPCRs) comprise the
largest family of transmembrane proteins. For
GPCR drug discovery, it is important that ligand
affinity is determined in the correct cellular environ-
ment and preferably using an unmodified receptor.
We developed a live cell high-content screen-
ing assay that uses a fluorescent antagonist,
CA200645, to determine binding affinity constants
of competing ligands at human adenosine-A1
and -A3 receptors. This method was validated as a
tool to screen a library of low molecular weight frag-
ments, and identified a hit with submicromolar
binding affinity (KD). This fragment was structurally
unrelated to substructures of known adenosine
receptor antagonists and was optimized to show
selectivity for the adenosine-A3 receptor. This tech-
nology represents a significant advance that will
allow the determination of ligand and fragment
affinities at receptors in their native membrane
environment.
INTRODUCTION
G protein-coupled receptors (GPCRs) comprise the largest
family of transmembrane proteins and represent major targets
for drug discovery, with over 40% of currently marketed drugs
acting at these cell surface receptors. Considerable advances
in our knowledge of GPCR structure have been recently
achieved from X-ray crystallography (Cherezov et al., 2007;
Chien et al., 2010; Hanson et al., 2012; Jaakola et al., 2008;
Rasmussen et al., 2011; Shimamura et al., 2011). This has led
to insights into the conformational changes that result during
receptor activation (Chung et al., 2011; Rasmussen et al.,
2011) and has provided opportunities for virtual screening of
molecular libraries and fragment-like ligands (de Graaf et al.,
2011; Kolb et al., 2009). In addition, availability of highly purified
detergent-solubilized receptor protein has enabled fragment
screening using biophysical approaches such as surface plas-
mon resonance and nuclear magnetic resonance (Congreve
et al., 2011). However, the act of detergent solubilization disruptsChemistry & Biology 19, 1105–111the local environment in which these membrane proteins nor-
mally reside and removes many of the ancillary proteins that
can provide allosteric influences on ligand-receptor interactions
(Kenakin, 2012).
It is now acknowledged that GPCRs can adopt multiple active
conformations as a consequence of protein-protein interactions
that can lead to the activation or attenuation of different signaling
pathways (Kenakin and Miller, 2010; Swaminath et al., 2004).
Furthermore, different agonists appear able to bias signaling in
favor of a particular downstream pathway, including those that
do not involve heterotrimeric G proteins (Azzi et al., 2003; Baker
et al., 2003; Whalen et al., 2011). It is also clear that the binding
affinity of antagonists can vary depending on the signaling
pathway and agonist that is being studied (Baker and Hill,
2007). These data suggest that intracellular signaling proteins
can elicit marked allosteric influences on the binding of both
agonists and antagonists to a particular GPCR (Kenakin and
Miller, 2010; Kenakin, 2012; Williams and Hill, 2009) and as
a consequence the cellular context in which binding affinities
are measured will have a major impact on drug screening
strategies. It is therefore imperative to derive methods for the
measurement of ligand-binding affinity in living cells, where the
integrity of the local membrane environment and receptor is
maintained under physiologic conditions.
Fluorescence-based assays have the sensitivity and resolu-
tion to monitor ligand-binding in single living cells, and high-
quality fluorescent ligands for GPCRs are now becoming
available (Daly et al., 2010; May et al., 2010; Middleton and
Kellam, 2005). The adenosine-A3 receptor (A3AR) belongs to
a family of four GPCRs (A1, A2A, A2B, and A3) (Fredholm et al.,
2011) that respond to adenosine and are attractive drug targets
for a number of pathophysiologic conditions including cancer,
ischemia, cardiovascular disease, and inflammation. We have
shown that fluorescent BODIPY630/650 (BY630) labeled
agonists can be used to monitor the kinetics of ligand-binding
to unmodified human adenosine-A1 (A1AR) and A3AR receptors
in real time at the single cell level by taking advantage of the
marked increase in quantum yield of the BODIPY fluorophore
in the local membrane environment of the receptor that occurs
as the ligand binds (May et al., 2010, 2011). We developed a
competition binding assay using a novel fluorescent antagonist
and a high-content screening system for the automated capture
and analysis of images. We show that measuring total image
intensity allowed accurate affinity values of antagonists at the
A1AR and A3AR to be determined. Furthermore, we demonstrate5, September 21, 2012 ª2012 Elsevier Ltd All rights reserved 1105
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Fluorescent Assay for Fragment Screening at GPCRsthat the assay can detect weakly binding low molecular weight
compounds.
The ability of the assay to detect low-affinity ligand-binding
molecules suggested that the assay may be amenable for frag-
ment screening approaches. Fragment-based drug discovery
uses a chemical library containing only small, low molecular
weight compounds and is a powerful and widely used tool in
drug discovery because it explores chemical space more effi-
ciently. A fragment screen often results in lead compounds
with a low molecular weight and complexity; desirable charac-
teristics for a drug candidate lead (Hopkins et al., 2004).
Biophysical methods such as X-ray crystallography, nuclear
magnetic resonance spectroscopy, surface plasma resonance,
and mass spectrometry are most commonly used for fragment
screening (Bartoli et al., 2006), and have been successfully
used to generate novel lead compounds against cytosolic
proteins such as kinases and proteases (Whittaker et al.,
2010). While structural information is now becoming available
on GPCRs (Cherezov et al., 2007; Chien et al., 2010; Hanson
et al., 2012; Jaakola et al., 2008; Rasmussen et al., 2011; Shima-
mura et al., 2011), the importance of the membrane environment
for their functional integrity and stability has made them less
amenable to analysis with biophysical techniques. Some
success has been achieved using highly purified detergent-solu-
bilized receptor protein that has been thermostabilized with
genetic mutations (Congreve et al., 2011). However, a major
concern is that this removes the GPCR from the intracellular
signaling proteins that may allosterically modify ligand-binding
behavior (Chung et al., 2011; Kenakin, 2012; Steyaert and Ko-
bilka, 2011; Williams and Hill, 2009). In this study, we show
that measurement of the binding of a fluorescent ligand to both
A1AR and A3AR in living cells can be used to screen a fragment
library and identify molecules with micromolar affinity, which can
discriminate between these two closely related receptor
subtypes.
RESULTS
A Fluorescent Xanthine Amine Congener, CA200645, as
a Fluorescent A3AR Antagonist
CA200645 (CellAura Technologies Ltd) is amodification of an ex-
isting fluorescent xanthine amine congener (XAC) analog (Brid-
don et al., 2004) with a polyamide linker connected to the
BY630 fluorophore (Figure 1A). To confirm that CA200645
retains antagonist properties at the A3AR, agonist concentration
response curves were generated in the presence of CA200645 in
Chinese hamster ovary (CHO) K1 cells stably expressing the
human A3AR and a reporter gene consisting of a cAMP response
element (CRE) promoter linked to a gene encoding secreted
placental alkaline phosphatase (SPAP) (A3-CRE-SPAP cells).
Measuring the levels of SPAP secreted from the cells gives an
indirect measure of cAMP concentration within the cells and for-
skolin (FSK) is added to allow the A3AR mediated Gi/o response
to be observed. Increasing concentrations of the agonist NECA
resulted in a concentration-dependent reduction in SPAP
production and incubation with increasing concentrations of
CA200645 caused parallel rightward shifts in the NECA response
curves (Figure 1B). Schild analysis revealed the logKb of
CA200645 at the A3AR to be 8.53 ± 0.10 (n = 3) with a Schild1106 Chemistry & Biology 19, 1105–1115, September 21, 2012 ª201slope not significantly different from unity, indicating its action
as a competitive antagonist.
Receptor-ligand interactions at the cell membrane were visu-
alized using confocal microscopy. A3-CRE-SPAP cells were
incubated with 25 nM CA200645 for 10 min at 37C and single
equatorial confocal images were obtained, which revealed clear
CA200645 fluorescence at the cell membrane (Figure 1C, upper
left panel). Specificity of the binding of CA200645 was estab-
lished by pre-incubation of cells with the A3AR antagonist
MRS1220 (100 nM, 30 min at 37C), which resulted in a substan-
tial reduction in the observed fluorescence (Figure 1C, lower left
panel). Specificity of CA200645 binding was also confirmed
using cells expressing the A3AR fused to yellow fluorescent
protein (YFP; A3-YFP) (Figure 1C, middle panels) with high levels
of colocalization seen between ligand and A3-YFP fluorescence.
In both cases, very low levels of CA200645 fluorescence were
seen in the cytoplasm, indicating that CA200645 mainly labels
cell surface receptors and does not readily cross the cell
membrane. To confirm this, A3-CRE-SPAP cells were incubated
with 25 nMCA200645 for 2 hr at 37C prior to imaging (Figure S1
available online), at which point clear membrane binding is still
observed with little cytoplasmic fluorescence.
The kinetics of CA200645 binding to the A3AR were investi-
gated using confocal microscopy performed at 37C.
CA200645 (25 nM) bound rapidly to A3-CRE-SPAP cell
membranes, and was maximal by 15 min (Figure 1D). Cells
were then washed twice with buffer and the dissociation of
CA200645 monitored for a further 20 min at 37C, after which
30% of ligand had dissociated from the cell membrane, indi-
cating that CA200645 dissociates slowly from the A3AR (Fig-
ure 1D). The equilibrium dissociation constant of CA200645
calculated from this data (pKD = 8.21 ± 0.12, n = 4) was similar
to that obtained from functional assays.High-Content Screening Using a Confocal Imaging Plate
Reader
The fluorescent A3AR antagonist CA200645 displayed many of
the desired characteristics required for use in a high-content
screening assay in live cells, including high affinity and a slow
off-rate. A3-CRE-SPAP cells were grown in 96-well plates and
incubated with increasing concentrations of three different
antagonists with varying A3AR affinities, prior to addition of
25 nM CA200645. Subsequently, a confocal imaging plate
reader (ImageXpress Ultra) was used for automated capture of
four images per well. These images (Figure 2A) showed a clear
decrease in membrane-bound CA200645 with increased
competitor concentration. As expected, the high-affinity A3AR
antagonist MRS1220 was able to displace CA200645 binding
at lower concentrations than the moderate affinity antagonist
XAC, while the A1AR specific antagonist DPCPX only displaced
CA200645 binding at the highest concentration used (10 mM).
Competition binding curves were generated using the mean of
total image intensity from each well (Figure 2B), and pKi values
were calculated using the Cheng-Prusoff equation, using the
Kb value for CA200645 (3.11 nM at A3AR) determined in the
CRE-SPAP gene transcription assay (Table 1). The pKi values
obtained using the fluorescent ligand-based competition binding
assay correlated well with the pKb values obtained for the same2 Elsevier Ltd All rights reserved
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Figure 1. Pharmacologic Characterization of CA200645
(A) The fluorescent ligand CA200645.
(B) Effect of increasing concentrations of the agonist, NECA, in the absence (d) and presence of 10 nM (-), 100 nM (:), and 1 mM (A) CA200645 on the SPAP
response to 1 mM FSK in cells expressing A3AR. Data are normalized to the response to 1 mM FSK and each data point represents mean ± SEM from three
separate experiments performed in triplicate.
(C) CHO cells expressing the A3AR or A3-YFP labeled with 25 nM CA200645, with and without preincubation with 100 nM MRS1220. Images shown are from
a single experiment representative of three performed.
(D) Association and dissocation kinetics of 25 nM CA200645. CHO A3AR cells were exposed to 25 nM CA200645 and confocal images were taken every 2 s for
20min. Cells were washedwith HBSS and images taken for a further 20min. Data representsmean ± SEM from four separate experiments in which each replicate
reflects the fluorescence intensity from the plasma membrane of ten cells.
See also Figure S1.
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Fluorescent Assay for Fragment Screening at GPCRscompounds in the CRE-SPAP gene transcription assays
including those with low affinity (R2 = 0.99; Figure 2C).
The assay was also able to quantify agonist displacement of
CA200645 binding (Figure 2D), with three A3AR selective
agonists, IB-MECA, 2-Cl IB-MECA, and HEMADO and the
nonselective adenosine receptor agonist, NECA inhibiting
CA200645 binding in a concentration-dependent manner
(pIC50s = 7.13 ± 0.16, 7.13 ± 0.17, 7.23 ± 0.23, and 5.93 ±
0.15, respectively, n = 4) to levels similar to that observed in
the presence of MRS1220. In contrast, only partial displacement
of CA200645 binding was observed with the A2AAR selective
agonist, CGS 21680.
CA200645 was also able to bind to the closely related human
A1AR expressed in CHO cells (CHO-A1 cells; (Cordeaux et al.,
2000) and antagonised calcium responses to NECA with a logKb
of8.40 ± 0.15 (n = 4) (Figure S2). In an equivalent high-content,
fluorescence-based binding assay for the A1AR, the affinities of
competing ligands, calculated from the inhibition of CA200645Chemistry & Biology 19, 1105–111binding, were consistent with its known pharmacology (Fig-
ure 2E), with DPCPX having the highest affinity at the A1AR;
and the A3AR selective antagonist triazolo-quinoxaline 1 (Lenzi
et al., 2006), the lowest (Table 1).
Although data acquisition only took 20 min per plate, and the
plate was read at room temperature using live cells, it was impor-
tant to consider the potential for dissociation of CA200645
during this step. No significant dissociation of CA200645 was
seen during image acquisition across the plate because the total
membrane binding of CA200645 in the first column (Figure 2A,
left side) was very similar to that in the last column (right side).
Quantification of this binding over a number of experiments
showed the total membrane intensity values for the last six wells
read represented 96.7 ± 2.5% (n = 11) of the membrane intensi-
ties in the first six wells.
Making use of data collection in two channels, it was also
possible to use the high-content screening assay for simulta-
neous determination of ligand-binding and a functional5, September 21, 2012 ª2012 Elsevier Ltd All rights reserved 1107
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Figure 2. High-Content Screening Allows Competition Binding Curves to be Generated and Affinity Values Obtained at Both the A3AR
and A1AR
(A) Montage of one plate of images obtained using high-content screening in CHOCRE-SPAP A3AR cells. The two blank wells at the bottom of the first column are
where the autofocusing of the plate was performed.
(B) Competition curves at the A3AR generated from the total image intensity for five adenosine receptor antagonists.
(C) Correlation between pKi values obtained using HCS and pKB values obtained in a functional SPAP assay.
(D) Competition curves at the A3AR for five different adenosine receptor agonists.
(E) Competition curves at the A1AR generated from the total image intensity in CHO-A1 cells for five adenosine receptor antagonists. Data are normalized to the
maximal intensity observed per experiment and each data point represents the mean ± SEM from four (D and E) or five (B) experiments performed in duplicate.
See also Figure S2.
Chemistry & Biology
Fluorescent Assay for Fragment Screening at GPCRsresponse. Using CHO cells expressing the A3R tagged on its C
terminus with YFP (CHO A3-YFP cells) simultaneous images of
A3AR internalization and binding of CA200645 could be captured
(Figure 3). Thus, two A3-selective agonists, 2-Cl IB-MECA and
HEMADO, stimulated A3-YFP internalization, while the A3-selec-1108 Chemistry & Biology 19, 1105–1115, September 21, 2012 ª201tive antagonist MRS1220 did not (Figure 3A). Measurement of
the binding of CA200645 30 min after addition of the above
agents in the same wells confirmed that all three compounds
inhibited CA200645 binding (Figure 3B). Quantification of A3AR
internalization using granularity analysis (Kilpatrick et al., 2010)2 Elsevier Ltd All rights reserved
Table 1. Binding Affinities of Literature Antagonists against the Adenosine A3AR and A1AR
A3AR A1AR
Fluorescent Ligand-Binding Assaya Functional SPAP Assayb Fluorescent Ligand-Binding Assaya
pKi n pKB n pKi n
1 8.51 ± 0.31 6 8.78 ± 0.16 3 5.93 ± 0.12 3
MRS1220 9.02 ± 0.22 6 9.29 ± 0.08 6 7.14 ± 0.38 3
XAC 7.85 ± 0.14 6 7.79 ± 0.32 6 7.54 ± 0.10 4
DPCPX 6.96 ± 0.02 6 6.76 ± 0.69 3 8.54 ± 0.17 4
ZM 241385 6.74 ± 0.07 5 6.39 ± 0.65 3 6.68 ± 0.11 3
PSB 603 7.25 ± 0.11 4 ND 7.38 ± 0.02 4
CGS 15943 8.18 ± 0.10 4 ND 8.95 ± 0.08 4
SCH 58261 6.73 ± 0.26 4 ND 7.29 ± 0.08 4
aValues obtained in a fluorescent adenosine receptor antagonist binding assay using whole, live cells expressing the A1AR or A3AR.
bMeasured by the shift of NECA-mediated inhibition of forskolin stimulated CRE-SPAP response in CHO CRE-SPAP cells expressing the A3AR.
Values represent mean ± SEM from n separate experiments and ND = not determined.
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Fluorescent Assay for Fragment Screening at GPCRsconfirmed that only IB-MECA and HEMADO caused A3-YFP in-
ternalisztion (Figure 3C).
Detection of Compounds Showing Low Binding Affinity
To determine if the high-content fluorescence-based competi-
tion binding assay could distinguish small molecules with low
affinity at the A3AR, the high-affinity A3AR antagonist 1 was de-
constructed into progressively smaller fragments 2–7 (Figure 4A).
These compounds were tested for their ability to displace
CA200645 binding at concentrations of up to 10 mM for the
lowest molecular weight molecules (Figure 4). A wide range of
affinities was measured for 2–7 (pKi values from 7.11 to < 2),
and the affinity of the fragments at the A3AR generally increased
with molecular mass gain and increasing structural complexity.
Small structural changes in some of the compounds resulted in
relatively large shifts in potency. For example, there was
a substantial increase in the binding affinity of quinoxaline-1,4-
dione 2 (pKi = 7.11 ± 0.17; n = 3) compared to the corresponding
hydrazone 3 (pKi = 5.58 ± 0.12, n = 3), presumably via a combina-
tion of conformational restriction and introduction of a new
hydrogen bond acceptor.
Screening of a Fragment Library
To determine whether high-content imaging of living cells could
be used to evaluate the binding of low-affinity compounds to the
A3AR, a 248 compound subset from a Maybridge ‘‘Rule of
Three’’ fragment library were tested for their ability to inhibit
the binding of CA200645 to the A3AR at a single concentration
of 1 mM (Figure 5). Figure 5A shows a representative selection
of 25 fragments with differing affinities for the receptor. Any
compound that inhibited CA200645 binding to within 10% of
that observed with 1 mM MRS1220 was taken forward for full
concentration analysis (Table S1). The pKi values for all 38 of
these compounds are given in Table S2 and the data and struc-
tures for the six most potent fragments are shown in Figures 5B
and 5C. DP 01095 was the most potent fragment from this
screen with a pKi value of 6.44 ± 0.18. Interestingly, pKi values
as low as 3.97 could be measured for these fragments (Table
S2). Using CHO A3-YFP cells as described previously, it was
confirmed that none of the fragments that underwent fullChemistry & Biology 19, 1105–111concentration analysis acted as agonists at the A3AR. Respre-
sentative images from cells treated with the six most potent
compounds are shown in Figure 5D.
Chemical Modification of a Lead Fragment to Provide
A3-Receptor Selectivity
Having identified DP 01095 as the most potent fragment, its
structure lent itself to address whether our assay was sensitive
enough to differentiate any early structure activity relationship
(SAR) profiles and/or receptor subtype selectivity through
further expeditious chemical elaboration. We therefore initially
synthesized two alternative structural isomers based on the
position of the anilino amine (Figure 6A) and assayed these
and the parent compound at both the A1AR and A3AR. For
both receptor subtypes the three isomers demonstrated a similar
rank order of affinity (Figures 6B and 6C); DP 01095 remained
the highest affinity A3AR compound (pKi = 6.48 ± 0.14) followed
by the 3-aminophenyl 8 (pKi = 5.49 ± 0.11), with the para-deriv-
ative 9 (41.2 ± 7.3% inhibition at 100 mM) displaying the weakest
affinity. Because DP 01095 remained the highest affinity lead
fragment for the A3AR, we elaborated this molecule via acylation
or alkylation of the anilino nitrogen to afford a focused 14-
member mini-library (compounds 10–23, Table S3; for synthetic
procedures, see Supplemental Experimental Procedures). Initial
screening against the A3AR resulted in an identifiable SAR with
the acylated anilines (10–16) displaying the largest inhibition of
fluorescent ligand binding when compared to the alkylated
derivatives 17–23 (Table S3). Only five compounds were
capable of inhibiting binding by >50% and a pKi was derived
for these compounds (Table S3). The 3-nicotinoyl amide deriva-
tive 10, displayed a 3-fold increase in affinity when compared
to DP01095 (Figure 6E), while only the furan 2-carboxamido
(11) and thiophene 2-carboxamido (12) derivatives showed
enhanced A3AR affinity compared to DP 01905. Rewardingly,
the enhancement of binding observed for 10, 11, and 12 was
not mirrored at the A1AR (Figure 6F), where all three ligands
inhibited binding by less than 50% at 10 mM. This confirmed
that acylated heteroaryl derivatives 10–12, unlike the DP
01095 precursor, displayed measurable A1AR/A3AR subtype
selectivity.5, September 21, 2012 ª2012 Elsevier Ltd All rights reserved 1109
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Figure 3. Simultaneous Measurement of
Ligand Binding andReceptor Internalization
Cells expressing A3-YFP were treated with in-
creasing concentrations of the agonists HEMADO
and 2-Cl IB-MECA and the antagonist MRS1220
for 30min prior to the addition of 25 nMCA200645.
CA200645 and YFP images were then obtained
on the ImageXpress Ultra confocal plate reader
after a further 30 min. Representative YFP images
show that in the absence of ligand A3-YFP is
clearly expressed at the cell surface and no
change in localization is observed in the presence
of MRS1220 (A). Clear redistribution of A3-YFP
is observed in the presence of high concentrations
of HEMADO or 2-Cl IB-MECA. Total image
intensity for CA200645 images was obtained
and granularity analysis was performed on YFP
image. Competition curves were obtained with
for MRS1220 (-), HEMADO (,), and 2-Cl IB-
MECA (d) (B) but only the agonists, HEMADO and
2-Cl IB-MECA, caused an increase in granule
count (C). Data are normalized to the maximal
intensity (B) observed or 10 mM 2-Cl IB-MECA
response (C) per experiment and each data point
represents the mean ± SEM from four experiments
performed in duplicate.
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It is now well established that GPCRs can adopt multiple confor-
mations to interact with different signaling pathways and this can
lead to the phenomenon of ligand bias (Kenakin andMiller, 2010;
Kenakin, 2012; Williams and Hill, 2009). It is thus a major chal-
lenge to develop multiwell plate assays for the measurement of
ligand affinity in living cells where the receptor is in the correct
cellular context, genetically identical to the native human
receptor and where the integrity of its local membrane environ-
ment is maintained. Here, we have succeeded in demonstrating
that a fluorescent XAC derivative, CA200645, can be used in
conjunction with a confocal imaging plate reader to provide an
appropriate assay that allows receptor characterization, frag-
ment screening and the evaluation of low-affinity compounds
in living cells expressing human A3 and A1 receptors.
The A3AR has been implicated as a drug target in a number of
pathophysiologic conditions including cancer, ischemia, cardio-
vascular disease, and inflammation. Historically, the affinity of
a ligand for a target receptor is most commonly determined by
measuring the ability of an unlabelled ligand to compete with
a single concentration of radiolabelled ligand at equilibrium in
isolated membrane preparations (Hulme and Trevethick, 2010).
An antagonist radioligand is the preferred probe of choice
because it avoids the complication of differential labeling of
active (R*) and inactive (R) receptor conformations by radiola-
belled agonists (Clark and Hill, 1995; Cordeaux et al., 2008).
However, radiolabelled antagonists for the A3AR have been re-
ported but are not available commercially (Varani et al., 2000).
Radiolabelled ligands have the advantage that the incorporation
of a radioisotope into a ligand does not affect its chemical struc-
ture, therefore assays tomeasure their binding are relatively easy
to set up and optimize. However, the final assay read-out is not in
real time and the assays are often conducted in disrupted
membrane preparations where cellular integrity has been lost.1110 Chemistry & Biology 19, 1105–1115, September 21, 2012 ª201This can have a major impact on binding characteristics as
a consequence of buffer composition, loss of membrane poten-
tial, and the presentation of buffer components and drugs to
both sides of the cell membrane. In addition, the safety risks
associated with handling radioligands in large screening
campaigns (particularly those based on 125I-labeled ligands)
and the associated legal and disposal requirements make alter-
natives highly preferred.
Here, we show that the fluorescent XAC derivative, CA200645,
is a high-affinity adenosine receptor antagonist that binds
specifically to cell-surface expressed A1AR and A3ARs. Its
slow off-rate from the receptors allowed imaging (at room
temperature) to take place following washout of the fluorescent
probe. These properties allowed a competition binding assay
to be developed in living cells based on measuring total image
intensity from confocal images captured and analyzed automat-
ically, which gave accurate and precise affinity values for known
ligands at the A3AR.We have shown that thismethod can resolve
a wide range of affinity values and identify subtle differences in
antagonist affinities. CA200645 also had a high affinity for the
A1AR expressed in CHO cells, allowing the same assay format
to be used to evaluate the selectivity of competing ligands for
A1AR and A3AR. It was notable that the selective A3AR and
A1AR antagonists, MRS 1220 and DPCPX, respectively, showed
the appropriate affinity profiles in these two receptor systems.
By using a high-affinity fluorescent antagonist such as
CA200645, we show that a fluoresecent competition binding
assay can be developed that directly detects the ligand. This re-
moves the need for genetic modification of the receptor, which is
a requirement of other GPCR ligand-binding assays that use
fluorescent ligands (Zwier et al., 2010), and would potentially
allow the assay to be used directly on cells and tissues that
endogenously express the A1AR and A3AR.
As mentioned, fragment-based assays are powerful tools in
drug discovery to explore chemical space more effectively.2 Elsevier Ltd All rights reserved
-10 -8 -6 -4 -2
0
20
40
60
80
100
120
7
6
5
4
3
2
1
log [compound] M
%
m
ax
im
al
in
te
g
ra
te
d
in
te
n
si
ty
A B
N
N
N
N
NH
O
O
OMe
1
8.51 +- 0.31
N
HN
N
N
O
O
OMe
2
7.11 +- 0.17
NH
HN
O
3
5.58 +- 0.12
N
N
H
OMe
N
NH
O
4
<4
N
NH2
5
<2
N
N OMe
6
3.28 +- 0.32
OMe
N
H
O
7
4.69 +- 0.35
Figure 4. Displacement of CA200645 Binding by Fragments Demonstrates that a Wide Range of Affinities Can Be Determined at the A3AR
(A) The high-affinity A3AR antagonist 1 was deconstructed into progressively lower molecular weight molecules 2–7, and the pKi values determined.
(B) Competition curves at the A3AR generated from the total image intensity. Data are normalized to themaximal intensity observed per experiment and each data
point represents mean ± SEM from at least three separate experiments performed in duplicate.
See also Figure S3.
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Fluorescent Assay for Fragment Screening at GPCRsHowever, the majority of previous work on GPCRs has involved
highly purified detergent solubilized receptors where removal of
the protein from its native cellular context may isolate it from the
normal allosteric influences of intracellular signaling and other
associated membrane proteins it experiences in living cells.
There are now a significant number of privileged molecular scaf-
folds that have been reported as possessing significant A3AR
subtype selectivity (Figure S3). The development of a live cell
ligand-binding assay for the A3AR allowed us to evaluate
whether fragment screening could be undertaken in an intact
cellular environment. From a library of 248molecules (Maybridge
‘‘Rule of Three’’), we were indeed able to assay and identify
a range of fragments that displayed binding affinities in the
micromolar range.
Analysis of the hits from our screen allowed us to ascertain if
we had successfully identified compounds containing structural
motifs present within established A3-selective ligands (Fig-
ure S3). For example, the 1,3-thiazole nucleus has been recently
confirmed as a key component in many adenosine receptor
antagonists (Figure S4A and associated references). Of the
248 compounds assayed, there were 20 examples of this
substructure within the library (two of which were embedded
in a benthiazole fragment). Of the 18 non-ring fused thiazole
variants, our assay identified five as hits (Figure S4A). However,
modeling studies performed to-date suggest that the key
receptor-ligand interactions are achieved through the substitu-
ents present on the heterocyclic ring rather the thiadiazole
itself (Miwatashi et al., 2008). One could therefore envisage
that with such simple fragments, binding via alternative geome-
tries is entirely probable and it was encouraging that the
more highly decorated heteroaryl-aryl linked hit fragments did
indeed possess the superior binding affinities; possible by virtue
of additional points of contact with the receptor binding site.
More rewarding, however, was the observation that our assay
identified the only 1,2,4-thiadiazole present within the library
and this overlaid well with recently established literature
compounds (Jung et al., 2004; van Muijlwijk-Koezen et al.,
2001) (Figure S4B). Indeed, simple acylation of the fragment’sChemistry & Biology 19, 1105–111aromatic amino group would naturally arrive at the nanomolar
affinity compounds illustrated in the literature. Our assay also
identified the sole quinazoline fragment within the library as
a hit. In addition, we were also able to identify three of the
four pyrimidines present. Crucially this included the only
example of a 2-phenylpyrimidine; a scaffold recently identified
as providing the basis of potent A3AR antagonists (Fig-
ure S4C) (Yaziji et al., 2011). Taken together, these and other
fragments identified from our screen serve as excellent exem-
plars that this fluorescence-based screening approach could
indeed generate important lead compounds in a drug discovery
program.
Ultimately however, from our library of 248 molecules we
identified our favored lead fragment DP 01095 with high affinity
(pKi = 6.44), which provided a chemical template for the design
of A3AR antagonists. 1H-Benzimidazol-2-yl systems have been
reported as antagonists of the A1AR, however with quinoline
and isoquinoline substitutents at the 2-position (Cosimelli
et al., 2011). The structure of DP 01095 was ideal to assess
whether our assay was sensitive enough to allow identification
of early SAR profiles and/or receptor subtype selectivity through
further chemical modification. A decrease in affinity was
observed as the anilino amine was relocated onto the meta- (8)
and para- (9) positions. The observed rank order of affinity at
the A3AR was ortho > meta > para and this SAR transposed
onto the A1AR, albeit with a minor yet concomitant reduction in
ligand affinities. Encouraged by these results, we undertook
further structural refinements through either acylation (10–16)
or alkylation (17–23) of the anilino amine of DP 01095 to afford
a focused 14-member mini-library of alkyl, aryl, and heteroaryl
functionalised benzimidazoles. The three heteroaryl carboxa-
mides (10–12) that displayed increased binding affinities for
the A3-receptor compared to DP 01095 were all demonstrated
to exhibit a much lower affinity for the A1-receptor. These data
suggest that confocal imaging based assays of fluorescent
ligand binding to transmembrane receptors expressed on whole
living cells, in combination with the data becoming available on
the crystal structure of a wide range of GPCRs, has the potential5, September 21, 2012 ª2012 Elsevier Ltd All rights reserved 1111
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Figure 5. Screening a Commercial Fragment Library Identifies Hits with Affinities of Less Than 10 mM
A total of 248 compounds from aMaybridge ‘‘Rule of Three’’ fragment library at a single concentration of 1 mMwere tested for their ability to inhibit the binding of
CA200645 at the A3AR.
(A) A representative selection of the inhibition observedwith 25 fragments and the controls, 1 mMMRS1220 (gray bars) and 1%DMSO (white bars). Any fragments
that inhibited CA200645 binding to within 10% of that observed with MRS1220 were defined as hits and full concentration response curves defined as described
in Figure 1.
(B) Concentration response curves of the top six fragment hits at the A3AR. Each data point represents mean ± SEM from four separate experiments performed
in duplicate.
(C) The chemical structure of the top six fragment hits with mean ± SEM pKi values shown below the structure.
(D) Representative images from A3-YFP expressing cells treated with 1 mM for 1 hr at 37
C of the top six compounds.
See also Tables S1 and S2.
Chemistry & Biology
Fluorescent Assay for Fragment Screening at GPCRsto revolutionise the drug discovery process involving this
receptor family.
SIGNIFICANCE
Development of new approaches that allow the screening of
both drug and fragment-like molecules at GPCRs in a live
cell format would be a significant addition to the drug
discovery process.We describe the development of a robust
competition binding assay for two such GPCRs, the adeno-
sine-A1 and -A3 receptors, which use a fluorescent antago-
nist ligand. This assay uses automated capture and analysis
of confocal images in a multiwell format to obtain quantita-
tive information on ligand-binding parameters in living cells,
allowing accurate determination of affinity values for litera-
ture antagonists. This assay has advantages over currently
describedmethodology because it is does not requiremodi-
fication of the receptor of interest and is ammeanable to
high throughput screening. We demonstrated that fragment
screening can be carried out on living cells and that a viable1112 Chemistry & Biology 19, 1105–1115, September 21, 2012 ª201chemical lead could be indentified. The highest affinity frag-
ment had a dissociation constant of less than 1 mM and, to
our knowledge, possessed a novel structure for an AR
antagonist. A small library of compounds based on this
lead fragment was synthesized and a higher affinity A3AR
antagonist was found which had little affinity at the A1AR.
High-throughout fragment screening using living cells could
address one of the major issues in the GPCR drug discovery
process because there is no need for receptor purification
and biophysical approaches.EXPERIMENTAL PROCEDURES
Chemicals and Synthesis
All transfection reagents and G418 were obtained from Invitrogen. Fetal calf
serum was obtained from PAA Laboratories and L-glutamine from Lonza.
MRS1220, DPCPX, ZM241385, IB-MECA and HEMADO were purchased
from Tocris Bioscience. All other biological reagents were obtained from
Sigma-Aldrich. CA200645 was obtained from CellAura Technologies. General
chemistry methods and the synthesis of 1 to 23 are described in the Supple-
mental Information.2 Elsevier Ltd All rights reserved
-8 -7 -6 -5 -4 -3
0
20
40
60
80
100
120
8
9
DP 01095
log [compound] M
%
m
a
x
im
a
l
in
t
e
g
r
a
t
e
d
in
t
e
n
s
it
y
-8 -7 -6 -5 -4 -3
0
20
40
60
80
100
120
9
8
DP 01095
log [compound] M
%
m
a
x
im
a
l
in
t
e
g
r
a
t
e
d
in
t
e
n
s
it
y
A B C
0
20
40
60
80
100
120
11
DP 01095
10
12
%
m
a
x
im
a
l
in
t
e
g
r
a
t
e
d
in
t
e
n
s
it
y
0
20
40
60
80
100
120
12
10
11
DP 01095
%
m
a
x
im
a
l
in
t
e
g
r
a
t
e
d
in
t
e
n
s
it
y
D E F
N
H
N
H2N
DP 01095
N
H
N
NH2
9
N
H
N
8
NH2
O
N
H
N
HN
O
N
10
N
H
N
HN
O
11
O
S
-9 -8 -7 -6 -5 -4 -3
log [compound] M
%
m
a
x
im
a
l
in
t
e
g
r
a
t
e
d
in
t
e
n
s
it
y
-9 -8 -7 -6 -5 -4 -3
log [compound] M
%
m
a
x
im
a
l
in
t
e
g
r
a
t
e
d
in
t
e
n
s
it
y
N
H
N
HN
12
Figure 6. Elaborated Derivates of DP 01095 Show Higher Affinity at the A3AR but Not at the A1AR
(A) Structure of the top fragment hit (DP 01095) and two derivatives, 8 and 9.
(B and C) These fragments were tested for their ability to inhibit the binding of CA200645 in cells expressing the A3AR (B) or A1AR (C). Each data point represents
mean ± SEM from six (B) and four (C) experiments performed in duplicate.
(D) Structure of three synthesized DP 01095 derivatives (10–12).
(E and F) The ability of these three compounds to inhibit the binding of 25 nMCA200645 in cells expressing the A3AR (E) or A1AR (F) receptor is shown. The dashed
lines show the curve obtained with DP 01095. Each data point represents mean ± SEM from four experiments performed in duplicate.
See also Figure S4 and Table S3.
Chemistry & Biology
Fluorescent Assay for Fragment Screening at GPCRsCell Culture and Generation of Stable Cell Lines
CHO-K1 cells stably expressing a cAMP response element-secreted placental
alkaline phophatase (CRE-SPAP) reporter gene (Baker et al., 2002) and
CHO-K1 cells stably expressing the human A1AR were maintained in
DMEM/F12 medium containing 10% fetal calf serum and 2 mM L-glutamine
at 37C in a humidified atmosphere of air/CO2 (19:1). To generate stable cell
lines, CHOCRE-SPAP cells were transfected with the pcDNA3.1 plasmid con-
taining cDNA encoding the full length humanA3AR or the human A3AR that was
fused in-frame with YFP (A3-YFP) using Lipofectamine according to manufac-
turer’s instructions. Transfected cells were subjected to selective pressure for
2 to 3 weeks through the addition of 1 mg/ml G418 to the normal growth
medium. Cells were dilution-cloned to obtain near-clonal cell lines. Cell lines
expressing A3-YFP were first screened for YFP fluorescence. Cell lines
(A3AR and A3-YFP) were then screened for a response in the CRE-SPAP
gene transcription assay.
CRE-SPAP Gene Transcription Assay
CHO CRE-SPAP cells stably expressing the A3AR were grown to confluence
in 96-well plates and on day prior to analysis, normal growth medium was
removed from the cells and replaced with serum free medium (DMEM/F12
containing 2 mM L-glutamine). On the day of analysis, the medium was
removed and replaced with fresh serum free medium containing the required
concentration of CA200645 and cells incubated for 1 hr at 37C/5%CO2. AfterChemistry & Biology 19, 1105–11130 min, the required concentration of the agonist NECA was added and cells
incubated for further 30 min at which time 1 mM forskolin was added. Cells
were incubated for 5 hr at 37C/5% CO2. Following the 5 hr incubation,
SPAP quantification was performed as described by Baker et al. (Baker
et al., 2002).
Confocal Microscopy
For single images, CHO CRE-SPAP cells stably expressing the A3AR or A3-
YFP were grown in Nunc Labtek 8-well plates, and images obtained using a
Zeiss LSM5 Exciter confocal microscope fitted with a 63x plan-Apochromat
1.4NA oil-immersion DIC objective at 37C. A 488 nm argon laser was used
to excite YFP and emission detected using a BP505-530 filter. BY630 was
excited using a 633 nmHeNe laser and emission detected using a LP650 filter.
Prior to imaging, normal growth medium was removed and cells were washed
twice in HEPES-buffered saline solution (HBSS; Briddon et al., 2004) and fresh
HBSS added for analysis. Cells were incubated with 25 nM CA200645 for
10 min at 37C before imaging. The specificity of CA200645 binding was
determined by pre-incubating cells with 100 nM MRS1220 for 30 min at
37C prior to the addition of CA200645.
To determine the kinetics of CA200645 binding, cells were grown on 22 mm
circular coverslips and imaged using a Zeiss LSM 510 confocal microscope
using a 403 1.3 NA oil-immersion objective (May et al., 2010). Coverslips
were mounted in an imaging chamber in HBSS, 25 nM CA200645 added5, September 21, 2012 ª2012 Elsevier Ltd All rights reserved 1113
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Fluorescent Assay for Fragment Screening at GPCRsand fluorescence and phase images collected every 2 s for 20min. BY630 was
excited using a 633 nmHeNe laser and emission detected using a LP650 filter.
After 20 min, cells were washed three times with HBSS, then fresh HBSS
added to the cells and images collected for a further 20 min. The change in
fluorescence intensity values were obtained on a single cell basis by drawing
a region of interest around the plasma membrane of ten cells per field using
the Zeiss AIM 4.2 software.High-Content Competition Binding Assay
CHO CRE-SPAP cells stably expressing the A3AR or A3-YFP or CHO A1 cells
were seeded into the central 60 wells of a 96-well clear-bottomed, black-
walled plate and grown to confluency. On the day of analysis, normal growth
medium was removed and cells washed twice with HBSS pre-warmed to
37C. Fresh HBSS was added to each well and the required concentration
of unlabelled compound added. The cells were incubated at 37C for
30 min, then 25 nM CA200645 was added to each well and the cells incu-
bated for a further 30 min at 37C/5% CO2. Buffer was then removed from
each well, cells washed once in HBSS and fresh HBSS added at room
temperature. Plates were immediately imaged using an ImageXpress Ultra
confocal plate reader which captured four central images per well using
a Plan Fluor 40x NA0.6 extra-long working distance objective. CA200645
was excited at 635 nm and emission collected through a 640-685 nm
band pass filter while YFP was excitated at 488 nm with emission collected
through a 525-550 nm band pass filter. Total image intensity was obtained
using a multi-wavelength cell scoring algorithm within MetaXpress software
(MetaXpress 2.0, Molecular Devices). Granularity analysis was performed
on YFP images using a granularity algorithm also within MetaXpress software
and granules were defined as having a diameter of 7–15 mm as previously
described (Kilpatrick et al., 2010).Commercial Fragment Library Screen
From the ‘‘Rule of Three’’ Fragment Library (Maybridge, UK), 248 compounds
were chosen by refining for a molecular weight of 100–350 Da, hydrogen bond
donors 0–3, hydrogen bond acceptors 1–3, TPSA between 10 and 60 A˚2 and
rotatable bonds 0–4. DMSO-d6 as was added to the compound (5 mg) to
achieve a concentration of 100 mM. Compounds were diluted to 10 mM in
HBSS and any compound that formed an obvious precipitate was not
screened. Compounds were screened at an initial concentration of 1 mM
and it was found that the high-content competition binding assay was tolerant
of concentrations of DMSO up to 1%. After initial screening, the purities of the
top 38 compounds were determined. This quality control analysis was per-
formed using a Shimadzu 2020 LCMS system, a Waters Sunfire C18 column
(3.5 mm, 2.1mm3 30mm), and Shimadzu Lab solutions software. Compounds
were analyzed by integration of the chromatogram peak at 254 nm and 220 nm
that corresponded to the designated compound mass, and were shown to
beR 95% pure at each wavelength.Data Analysis
All data were fitted using Prism 5 (GraphPad Software). Data analysis for esti-
mating pKB values from the CRE-SPAP gene transcription, calcium mobiliza-
tion assay and the kinetic analysis of CA200645 binding can be found in
Supplemental Experimental Procedures. All competition binding curves with
the fluorescently labeled antagonist were fitted to the following equation to
calculate the binding affinity (Ki) of the ligand to the receptor:
Ki =
IC50
1+
½L
KD
;
where [L] is the concentration of CA200645 in nM, KD is its KD in nM calculated
from functional assays and the IC50 is calculated from the following equation:
% inhibition of specific binding=
1003 ½A
½A+ IC50 ;
where [A] is the concentration of competing drug and the IC50 is the molar
concentration of the ligand required to generate 50% inhibition of specific
binding.1114 Chemistry & Biology 19, 1105–1115, September 21, 2012 ª201SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.chembiol.2012.07.014.
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